Nuroflux
Improving stroke patient outcomes with continuous real-time neurological monitoring.
At a glance
-
Development stage
Prototype developed
-
Investment stage
Pre-Seed
-
UNSW affiliation
UNSW Founders startup
-
Technology readiness level
TRL-6
A wearable medical device that continuously monitors patients for early detection of neurological deterioration.
Neurological deterioration is the cause of death for 17.6% of stroke patients. Current detection methods rely on CT scans every 24 hours and subjective nursing assessments. Nuroflux is developing a wearable medical device that allows for continuous monitoring and better patient outcomes.
-
Nuroflux is developing a wearable medical device for the continuous monitoring of brain blood-flow and activity in hospitalised stroke patients to provide real-time detection of neurological deterioration. Faster detection of these events will enable faster intervention, leading to improved patient outcomes. Continuous monitoring will also ease the burden on nurses to perform time-consuming assessments. One neurologist commented that the Nuroflux device “represents the Holy Grail” that clinicians are seeking. Nuroflux will sell devices to hospitals and provide a subscription service for its software platform, data storage and maintenance.
-
- Neurological deterioration (e.g. a secondary stroke) occurs in up to 40% of all stroke patients with up to 44% dying as a result (17.6% of all stroke patients).
- Standard care relies on CT scans every 24-hours and subjective physical nursing assessments.
-
- Hospitals (comprehensive stroke centres)
- Engaged 30+ neurologists worldwide
-
- Ongoing clinical trial with positive preliminary results
- Additional studies with Yale Medical School and The Garvan Institute of Medical Research
- Patent granted in Japan and China, accepted in Australia and the USA, under examination in Europe, South Korea, and India
- Upcoming FDA pre-submission meeting
Discover more UNSW spinouts
Search our catalogue of active spinouts and tech for license.